Trial Profile
A Phase I Trial of Lapatinib in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Adverse reactions
- 22 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Dec 2009 Planned end date (Apr 2007) added as reported by ClinicalTrials.gov.
- 23 Nov 2006 New trial record.